Display options
Cite
Chapuis N, Poulain L, Birsen R, et al. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Front Oncol. 2019;9:405doi: 10.3389/fonc.2019.00405.
Chapuis, N., Poulain, L., Birsen, R., Tamburini, J., & Bouscary, D. (2019). Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Frontiers in oncology, 9405. https://doi.org/10.3389/fonc.2019.00405
Chapuis, Nicolas, et al. "Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia." Frontiers in oncology vol. 9 (2019): 405. doi: https://doi.org/10.3389/fonc.2019.00405
Chapuis N, Poulain L, Birsen R, Tamburini J, Bouscary D. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Front Oncol. 2019 May 22;9:405. doi: 10.3389/fonc.2019.00405. eCollection 2019. PMID: 31192118; PMCID: PMC6540604.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2019 May 22;9:405. doi: 10.3389/fonc.2019.00405. eCollection 2019.

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.

Frontiers in oncology

Nicolas Chapuis, Laury Poulain, Rudy Birsen, Jerome Tamburini, Didier Bouscary

Affiliations

  1. INSERM U1016, Institut Cochin, Paris, France.
  2. CNRS UMR8104, Paris, France.
  3. Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France.
  4. Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.
  5. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Paris, France.
  6. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Paris, France.

PMID: 31192118 PMCID: PMC6540604 DOI: 10.3389/fonc.2019.00405

Abstract

Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. Targeting metabolic activities offers a wide range of therapeutic possibilities which are applicable to acute myeloid leukemia (AML). Indeed, in addition to the IDH1/2-mutated AML model which established the proof-of-concept for specifically targeting metabolic adaptations in AML, several recent reports have expanded the scope of such strategies in these diseases. This review highlights recent findings on metabolic deregulation in AML and summarizes their implications in leukemogenesis.

Keywords: acute myeloid leukemia; amino-acid; fatty acid oxidation; glycolysis; hematopoiesis; metabolism; oxidative phosphorylation; targeted therapy

References

  1. Science. 1956 Feb 24;123(3191):309-14 - PubMed
  2. Cell Metab. 2008 Jan;7(1):11-20 - PubMed
  3. J Exp Med. 2008 Sep 29;205(10):2397-408 - PubMed
  4. Br J Haematol. 2009 Feb;144(3):350-7 - PubMed
  5. Science. 2009 May 22;324(5930):1029-33 - PubMed
  6. J Clin Invest. 2010 Jan;120(1):142-56 - PubMed
  7. Cancer Cell. 2010 Mar 16;17(3):225-34 - PubMed
  8. Cell Cycle. 2010 May 15;9(10):2008-17 - PubMed
  9. Cell Stem Cell. 2010 Sep 3;7(3):380-90 - PubMed
  10. J Leukoc Biol. 2011 Jan;89(1):51-5 - PubMed
  11. Nature. 2010 Dec 2;468(7324):701-4 - PubMed
  12. Cancer Cell. 2010 Dec 14;18(6):553-67 - PubMed
  13. Anticancer Agents Med Chem. 2011 Nov;11(9):799-809 - PubMed
  14. Nat Med. 2012 Sep;18(9):1350-8 - PubMed
  15. Cell Stem Cell. 2013 Jan 3;12(1):49-61 - PubMed
  16. Cell Stem Cell. 2013 Jan 3;12(1):62-74 - PubMed
  17. Cell Stem Cell. 2013 Mar 7;12(3):329-41 - PubMed
  18. Nat Rev Cancer. 2013 Apr;13(4):227-32 - PubMed
  19. Science. 2013 May 3;340(6132):622-6 - PubMed
  20. Leukemia. 2013 Nov;27(11):2129-38 - PubMed
  21. J Proteome Res. 2013 Oct 4;12(10):4393-401 - PubMed
  22. Blood. 2013 Nov 14;122(20):3521-32 - PubMed
  23. Exp Hematol. 2014 Apr;42(4):247-51 - PubMed
  24. Nat Rev Mol Cell Biol. 2014 Apr;15(4):243-56 - PubMed
  25. Cancer Invest. 2014 Jul;32(6):241-7 - PubMed
  26. Blood. 2014 Sep 4;124(10):1645-54 - PubMed
  27. Cell. 2014 Sep 11;158(6):1309-1323 - PubMed
  28. Science. 2015 Jan 9;347(6218):194-8 - PubMed
  29. Nat Med. 2015 Feb;21(2):178-84 - PubMed
  30. Blood. 2015 Mar 26;125(13):2120-30 - PubMed
  31. Blood. 2015 Jun 25;125(26):4060-8 - PubMed
  32. Apoptosis. 2015 Aug;20(8):1099-108 - PubMed
  33. Cancer Cell. 2015 Jun 8;27(6):864-76 - PubMed
  34. Cancer Res. 2015 Jun 15;75(12):2478-88 - PubMed
  35. Blood. 2015 Sep 10;126(11):1346-56 - PubMed
  36. Blood. 2015 Oct 15;126(16):1925-9 - PubMed
  37. Cell Stem Cell. 2015 Nov 5;17(5):585-96 - PubMed
  38. Cell Death Discov. 2015 Aug 17;1: - PubMed
  39. Tumour Biol. 2016 May;37(5):6027-34 - PubMed
  40. Cell Stem Cell. 2016 Feb 4;18(2):214-28 - PubMed
  41. Blood. 2016 Jul 14;128(2):253-64 - PubMed
  42. N Engl J Med. 2016 Jun 9;374(23):2209-2221 - PubMed
  43. Hematol Oncol. 2017 Dec;35(4):769-777 - PubMed
  44. Oncol Lett. 2016 Jul;12(1):334-342 - PubMed
  45. Cell Stem Cell. 2016 Jul 7;19(1):23-37 - PubMed
  46. Sci Rep. 2016 Aug 02;6:30693 - PubMed
  47. Blood. 2016 Oct 13;128(15):1944-1958 - PubMed
  48. Mol Cell. 2016 Sep 15;63(6):1006-20 - PubMed
  49. Cancer Cell. 2016 Nov 14;30(5):779-791 - PubMed
  50. Sci Rep. 2016 Oct 19;6:35561 - PubMed
  51. Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6669-E6678 - PubMed
  52. Oncotarget. 2016 Nov 29;7(48):79722-79735 - PubMed
  53. Oncotarget. 2016 Dec 13;7(50):83208-83222 - PubMed
  54. Leukemia. 2017 Jun;31(6):1434-1442 - PubMed
  55. EBioMedicine. 2016 Dec;14:55-64 - PubMed
  56. Cell Death Dis. 2016 Dec 8;7(12):e2516 - PubMed
  57. Blood. 2017 Feb 9;129(6):771-782 - PubMed
  58. Blood. 2017 Mar 9;129(10):1320-1332 - PubMed
  59. Cancer Res. 2017 Mar 15;77(6):1453-1464 - PubMed
  60. Comput Biol Chem. 2017 Apr;67:150-157 - PubMed
  61. Leukemia. 2017 Oct;31(10):2143-2150 - PubMed
  62. J Exp Med. 2017 Mar 6;214(3):719-735 - PubMed
  63. PLoS One. 2017 Feb 16;12(2):e0168781 - PubMed
  64. Leukemia. 2017 Nov;31(11):2326-2335 - PubMed
  65. BBA Clin. 2017 Mar 08;7:105-114 - PubMed
  66. Cancer Discov. 2017 Jul;7(7):716-735 - PubMed
  67. Blood. 2017 Aug 10;130(6):722-731 - PubMed
  68. Blood. 2017 Oct 5;130(14):1649-1660 - PubMed
  69. Sci Rep. 2017 Sep 12;7(1):11253 - PubMed
  70. Exp Hematol. 2018 Feb;58:52-58 - PubMed
  71. Nature. 2017 Nov 16;551(7680):384-388 - PubMed
  72. Nat Commun. 2017 Dec 4;8(1):1903 - PubMed
  73. Clin Cancer Res. 2018 May 1;24(9):2060-2073 - PubMed
  74. Blood. 2018 Apr 12;131(15):1639-1653 - PubMed
  75. Nat Med. 2018 Jul;24(7):1036-1046 - PubMed
  76. Blood. 2018 Aug 30;132(9):911-923 - PubMed
  77. Cancer Cell. 2018 Oct 8;34(4):659-673.e6 - PubMed
  78. Blood. 2019 Jan 3;133(1):7-17 - PubMed
  79. Int J Mol Sci. 2018 Oct 25;19(11):null - PubMed
  80. Nat Med. 2018 Dec;24(12):1859-1866 - PubMed
  81. Cancer Cell. 2018 Nov 12;34(5):724-740.e4 - PubMed

Publication Types